Clinical trial NCT01658605: A Study to Investigate the Efficacy and Safety of GSK1605786 for Treatment of Patients With Active Ulcerative Colitis
Official title: A Phase II, 20-week, Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Proof of Concept Study to Investigate the Efficacy and Safety of GSK1605786 for Treatment of Patients With Active Ulcerative Colitis
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Colitis, Ulcerative
Keywords: GSK1605786
ulcerative colitis
CCR9 antagonist
proof of concept
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2012-08-07
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: GSK1605786 is an oral antagonist specific for the chemokine receptor CCR9 in development for treatment of small bowel and colonic Crohn's disease (CD). The purpose of this Phase II proof of concept study is to investigate the efficacy and safety of GSK1605786 (500 mg twice daily) administered orally for 16 weeks for the treatment of patients with active ulcerative colitis (UC). A key secondary objective is to understand the mechanism by which GSK1605786 is acting and to this end samples will be collected to confirm the degree of inhibition of CCR9 on T lymphocytes in the blood of patients, and to explore the relationship between concentration of drug and changes in lymphocyte and antigen presenting cell populations in the peripheral circulation and in the colon. Patients recruited at specified investigational sites will be invited to participate in an optional sub-study to explore the effects of GSK1605786 on trafficking of technetium labelled T cells using Single Photon Emission Computerized Tomography (SPECT). Specifically, the technique will be used to follow trafficking to large intestine and thymus and findings linked to pharmacokinetics of GSK1605786, receptor occupancy and clinical efficacy outcomes


Eligibility criteria: Inclusion Criteria:

* Male or female aged 18 and over at the time of signing the informed consent.
* A female subject of child-bearing potential is eligible to participate if she agrees to use one of the contraception methods listed in Section 8.1 for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until completion of the follow-up visit.
* Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form, prior to any of the screening procedures including discontinuation of prohibited medication.
* At screening (visit 1): patients with a clinical history and examination suggestive of active UC for at least 3 months despite at least 2 weeks treatment with oral \>2.4g/day mesalazine / mesalamine or equivalent.
* At screening/randomization (visit 2):

  * Presence of active UC spread beyond the rectum (inflammation extending ≥ 15cm from anal verge) as evidenced by flexible sigmoidoscopy or colonoscopy during the screening window.
  * AND MAYO score of 5 - 10 inclusive.
* AST and ALT \< 2xULN; alkaline phosphatase and bilirubin ≤ 1.5xULN (isolated bilirubin \>1.5xULN

Exclusion Criteria:

* If female, is pregnant, has a positive pregnancy test or is breast-feeding.
* Confirmed diagnosis of celiac disease, those who follow a gluten-free diet to manage symptoms of suspected celiac disease and subjects with positive serologic test for Tissue transglutaminase, tTG.
* Subjects who have received immunisation with a live vaccine e.g. measles, mumps, rubella (each as in MMR vaccine), oral polio, varicella, yellow fever, within 4 weeks of screening and throughout the study, with the exception of influenza vaccine.
* Known or suspicion of CD, indeterminate colitis, microscopic colitis, ischaemic colitis or radiation-induced colitis, based on medical history, endoscopy and/or histological findings.
* Subjects with imminent need for surgery for UC in the opinion of the investigator.
* Subjects where assessment of MAYO score is likely to be confounded by previous surgery (for example colectomy, ileostomies, colostomies or rectal pouches).
* Subjects requiring enteral or parenteral feeding.
* Use of prohibited medications within their specified timeframes (see Section 9).

  * 5-Aminosalicylic acid enema: within 2 weeks of screening and throughout study
  * Topical (suppository) 5-Aminosalicylic acid: at screening and throughout study
  * Biologic use: within 12 weeks of screening and throughout study
  * Corticosteroids use: Oral, rectal or parenteral corticosteroids within 4 weeks of screening and throughout study
  * Antibiotics: Intravenous antibiotics within 8 weeks of screening and throughout study (oral antibiotics are permitted where they have been used for \>4 weeks with stable dose for ≥2 weeks prior to screening)
  * Probiotics: within 4 weeks of screening (patients who initiated probiotics or prebiotics more than 4 weeks prior to screening should continue use throughout study)
  * NSAIDs: Within 7 days of screening and throughout the study (except low dose aspirin (≤325 mg/day) which may be continued for cardioprotection)
  * Digoxin: or related cardiac glycoside (e.g. digitoxin, deslanoside, lanatoside C, metildigoxin) use at any time during screening and throughout the study.
* Known HIV infection
* A positive HBsAg, Anti-HBc, or Hepatitis C antibody result at screening or documented positive result within 3 months of screening.
* Known varicella, herpes zoster, or other severe viral infection within 6 weeks of screening.
* Active or latent tuberculosis (TB) infection:

  * The subject has a history of TB disease or latent TB infection, in the absence of documented adequate therapy for same.
  * Suspicion of current TB disease (including extra pulmonary TB disease such as tuberculosis enteritis) or latent tuberculosis infection, as evidenced by positive QuantiFERON-TB Gold test, or T-SPOT.TB test.
* Current or chronic history of liver disease or known hepatic or biliary abnormalities including primary sclerosing cholangitis (with the exception of Gilbert's syndrome or asymptomatic gallstones).
* QTc ≥450 msec (≥480msec for those with Bundle Branch Block).

  * either QTcb or QTcf, machine or manual overread, males or females. The QT correction formula used to determine exclusion and discontinuation should be the same throughout the study.
  * based on single QTc value of ECG obtained over a brief recording period.
* The subject has a concurrent illness or disability that may affect the interpretation of clinical data, or otherwise contraindicates participation in this clinical study (e.g., an unstable cardiovascular, autoimmune, congenital or acquired immunodeficiency, renal, hepatic, pulmonary, endocrine, metabolic, gastrointestinal, haematologic, or neurological condition or mental impairment).
* The subject has current evidence of, or has been treated for a malignancy within the past 5 years (other than localised basal cell, squamous cell skin cancer, cervical dysplasia, or cancer in situ that has been resected).
* Use of any investigational drug within 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer) prior to screening
* Medical history of sensitivity to any of the components of GSK1605786 (microcrystalline cellulose, colloidal silicon dioxide, crospovidone, magnesium stearate, gelatin).
* Prior exposure to GSK1605786: Any previous exposure to GSK1605786 (formerly ChemoCentryx compound CCX282-B).
* Known positive stool culture for enteric pathogens
* Positive immunoassay for C. difficile.
* Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period (with the exception of subjects involved in the optional scintigraphy sub-study, where no more than 700 mL of blood will be collected over the duration of the study, including any extra assessments that may be required).

Primary outcomes:
measure: Efficacy of GSK1605786 at week 12 following twice daily administration at 500 mg in patients with active UC.
timeFrame: 12 weeks
Secondary outcomes:
measure: safety and tolerability of GSK1605786 in patients with active UC following repeat dosing continued for up to 16 weeks
timeFrame: 16 weeks
measure: The time course of the efficacy of GSK1605786
timeFrame: 16 Weeks
measure: The anti-inflammatory activity of GSK1605786 in patients with active UC
timeFrame: 16 Weeks
measure: The effects of GSK1605786 on quality of life in patients with UC
timeFrame: Baseline, week 12, week 16
measure: The systemic pharmacokinetics (PK) of GSK1605786 following twice daily administration at 500 mg in patients with active UC.
timeFrame: DaysBaseline, week 4, week 8, week 12, week 16
measure: CCR9 occupancy (RO) in peripheral blood
timeFrame: 12 Weeks
Other outcomes:
Locations:
city: Leuven
country: Belgium
facility: GSK Investigational Site
city: Amsterdam
country: Netherlands
facility: GSK Investigational Site
city: Cambridge
country: United Kingdom
facility: GSK Investigational Site
state: Cambridgeshire
city: Southampton
country: United Kingdom
facility: GSK Investigational Site
state: Hampshire
city: Oxford
country: United Kingdom
facility: GSK Investigational Site
state: Oxfordshire
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References: